Beer, T. M., Vogelzang, N., Bartůňková, J., Miller, K., Oh, W., Oudard, S., . . . Gerritsen, W. R. (2015). Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer. J Immunother Cancer.
Citação norma ChicagoBeer, Tomasz M., et al. "Autologous Dendritic Cell Immunotherapy (DCVAC/PCa) Added to Docetaxel Chemotherapy in a Phase III Trial (viable) in Men With Advanced (mCRPC) Prostate Cancer." J Immunother Cancer 2015.
Citação norma MLABeer, Tomasz M., et al. "Autologous Dendritic Cell Immunotherapy (DCVAC/PCa) Added to Docetaxel Chemotherapy in a Phase III Trial (viable) in Men With Advanced (mCRPC) Prostate Cancer." J Immunother Cancer 2015.